Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat for Anemia in Pediatric CKD
NCT04621331Phase 3Withdrawn
- Sponsor
- FibroGen
- Start
- May 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of roxadustat in anemia, sponsored by FibroGen. Primary endpoint: Proportion of patients with mean Hb ≥ 11.0 g/dL. Planned start May 2022; status: withdrawn.
02
Drugs
roxadustat
03
Conditions
anemia
Beyond the preview
Go deeper on NCT04621331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04621331.